earn preview select biotech
earn approach provid thought select larg mid-cap biotech
compani within coverag earn preview
celg th-tse glpg updat model
adjust number price target see tabl summar chang page overal
season especi come one-tim benefit inflat mani co
revenues/earn like limit potenti signific beat though consensu
number mostli alreadi reflect beyond number would look signal
proactiv capit deploy plan pipelin progress across space
could spark enthusiasm around growth larger-cap name comfort around
de-risk among smid-cap though volatil like continu slow
sustain polit rhetor drug price keep mani investor sidelin see
increasingli attract opportun group
top pick pt hiv hcv revenu close in-lin though believ
base analysi latest prescript trend street may fulli recogn mix
shift favor biktarvi estimate beat epclusa estimate beat expens mani
legaci product expect look soft atripla vs con descovi vs
harvoni vs recal eu hiv sale benefit one-tim
rebat adjust see underappreci cannib continu next year believ
total street consensu hiv sale est still look approxim achiev even driven
biktarvi dynam benefit gild hiv life cycl reduc diversif
ep estimate slightli consensu vs con expect earn call focu
use capit bigger-pictur growth strategi continu see gild valuat substanti
underappreci cash flow durabl core busi hiv car-t hcv option
pipelin partnership bd capac
sector perform pt rx/sale data suggest continu steadi volum ms
franchis q-o-q variabl inventori discount/allow fluctuat believ
continu show resili despit recent competitor launch tecfidera beat
vs con tysabri vs con believ spinraza mainli in-lin
expect vs con contribut in-lin top slightli above-
consensu bottom line vs con said medium/long-term ms sma
franchis risk remain concern exagger year pipelin setback continu lack
transform bd believ risk pose upcom tecfidera ip develop expect limit
franchis protect vumer addit risdiplam results/regulatori progress on-going
zolgensma launch like cap share appreci signific pipelin driver emerg
outperform pt expect cf franchis continu perform well
continu symdeko growth offset potenti orkambi cannib kalydeco stabil
expect modest beat top line overal cf franchis vs consensu addit
expect tripl combin like reach market shortli drive renew interest given
potenti widespread awar rapid uptak cf patient popul help drive
best-in-class growth margin
continu page
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
earn preview select biotech
continu cover
cont continu see underappreci valu base cf franchis alon
expect updat broaden pipelin particularli program
strong rational view multipl shots-on-go help share break current
outperform pt expect exondi revenu in-line/slightli
consensu est vs con believ larger focu
signal progress regulatori manufactur front wouldnt necessarili
expect signific develop time earn release/cal continu
believ lgmd function data near-term coupl regulatory/manufactur updat
mid-year could begin shift sentiment posit fuel signific share
appreci current level minor model updat adjust casimersen time
adjust tgt
outperform pt follow strong support recent
script analysi expect ingrezza continu growth trajectori td see potenti
modest beat estimate vs con despit season headwind could
reinforc long-term prospect help share bounc back follow recent weak
believ like abl continu build presenc td base kol
feedback support drug profil see addit upsid potenti given
pursuit huntington chorea new indic includ est peak
market opportun annual revenu po would also look
updat plan contract call remain somewhat cautiou
abbv-partn orilissa estimate less royalti vs consensu see
unappreci valu pipelin notabl led nbix program expect
updat expect rel near-term reassur potenti
diversifi around ingrezza could possibl catalyz share upsid
outperform pt expect revenu translarna vs con
emflaza vs con come slightli expect
histor light especi translarna q-to-q variability/season
base larg ex-u order pattern expect larg ex-u order come prior ye
vs time uncertain per management pull-through expand emflaza label
translarna approv brazil still help comfort meet full-year
dmd guidanc continu steadi dmd base growth recent stock
weak perhap due higher expect gt-aadc mileston requir partial
catalyz capit rais coupl cool neuro expect gener
derisk ahead datapoint perceiv binari risdiplam data
think creat attract entri point remain optimist risdiplam regulatori path
lt opportun believ next-gen splice modul well gene therapi
program move forward start receiv credit platform
sector perform pt expect jakafi come near consensu
vs con qoq growth driven continu solid execut offset typic
season slow-down believ continu good expens control could enabl
bottom-lin beat call would expect focu sever upcom gvhd readout
jakafi itacitinib see balanc setup data follow kol
feedback note promis trial also highlight sever clinic
competit risk well progress prophylact approach could limit
out-year expect maintain commerci execut jakafi continu expect
earn preview select biotech
in-lin trade number pipelin readout could drive meaning revenu
sector perform pt expect hcv royalti come
consensu expect estimate vs con given greater volum declin
hcv market overal despit net stabl share mavyret back-calcul may
increas declin ex-u hcv sale harder
forecast see track toward vs abbv guidanc follow recent
model updat reflect lower po nash asset ph ii data link
believ hcv trend also suggest modestli lower floor valu base royalti stream
lower tgt would expect focu call around
progress compani pipelin asset includ rsv drug
continu show promis data may long develop road hbv
candid substanti addit downsid may limit given royalti floor
strong cash posit believ meaning upsid would requir pipelin asset
becom de-risk
outperform pt script trend suggest gradual steadi demand growth
expect ww ocaliva sale pbc come line consensu keep
track beat top end full-year guidanc along
belief abl brand/pric differ nash believ also help
reaffirm solid revenu floor follow recent nda submiss oca nash
expect much call center around commerci launch prep color around
anticip plan price potenti label scenario indic continu
view multi- lt opportun nearli appreci current share valu
celg sector perform pt expect rel uncontroversi quarter
revlimid otezla line trx/sale trend indic potenti beat pomalidomid
estimate vs con abraxan estimate vs con
help catalyz slight help ep beat estimate vs con expect street
focu cvr valu deal close approach adjust pt reflect updat
outperform pt cover miller im sale trend growth
look strong reflect acceler retail segment uptak anticip
nuplazid revenu beat expect estimate vs con keep sale
track come upper end compani current guidanc
estimate also highlight recent initi see page believ
anoth strong quarterli earn could reinforc overal market opportun
pdp see underappreci well increas enthusiasm among investor
larger dementia-rel psychosi market late-break ctad harmoni data
decemb approach overal estimate pdp drp indic could grow
annual support floor valuat nearli price stock price
current level -- upsid opportun indic like mdd
outperform pt model xpovio sale quarter
approxim consensuss view xpovio commerci perform first
quarter help establish floor pivot boston data earlier-lin mm
believ like larger near-term focu remain bullish potenti posit
readout boston base prior clinic data stomp fda shift opinion
earlier year view data recent breakfast management would look
earn preview select biotech
addit detail timing/bar second interim analysi expect
control arm activ call take opportun updat model
account recent royalti agreement hcr partner moder estim
dlbcl given evolv competit landscap progress mm
outperform pt base rx sale trend analysi heplisav-b look
continu steadi sale growth run estimate sale quarter slightli
con est revenu continu look track slightli exceed compani
guidanc year believ consist uptak like revenu
durabl space help street start better appreci valu opportun
share
th-tse sector perform pt estimate trogarzo sale slightli
con reflect steadi launch uptak fewer new patient start compar
last quarter though off-set slightli higher con egrifta estimate vs con
given lower est out-year trogarzo tail pt decreas
launch trend could support recent announc extens studi data
reinforc robust antivir activ drug increas import control viru
outcom expect focu call trogarzo uptak dynam european
launch plan link updat regulatori path egrifta hiv patient comorbid
glpg sector perform pt vs take opportun make sever minor
updat glpg model includ tweak filgotinib ra po out-year revenu
potenti reflect regulatori competit develop adjust target
stat sell day vs fx eur/usd bp q-o-q unfavor usd
strength biggest potenti beat includ biktarvi con epclusa
con celg abraxan biib tysabri con inci olumi
royalti con notabl miss includ harvoni con
vosevi con descovi con odefsey con ptct
translarna mavyret royalti con
new prior estim shown incom statement follow page
price rate adjust
earn preview select biotech
earn preview select biotech
estim mm except per share item estimatesconsensu taf earn preview select biotech
medium-term
hcv hiv
est base
ra po
penetr
progress
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
capit market estim compani report consensu
minor chang ms franchis revenu base rx project
slightli decreas ocrevu share rrm out-year due ofatumumab competit
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand vertex
earn preview select biotech
estim mm except per share item estimatesconsensu cf earn preview select biotech
adjust cf franchis revenu est base rx trend
increas po tripl combin eu
moder medium-term ex-u estim base recent updat reimburs
account recent agreement semma ribometrix
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand sarepta
earn preview select biotech
adjust share count margin base latest file
push casimersen launch
earn preview select biotech
sarepta inc thousand except per share golodirsen eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens exondi litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom neurocrin
earn preview select biotech
earn preview select biotech
slightli increas ingrezza estim base rx trend
ad huntington chorea addit indic ingrezza/valbenazin
adjust spend account explor ingrezza addl indic like hd
incom statement thousand except td- hc- revenu gener oper incom expens incom expens tax provision- comprehens incom net incom per share outstand share outstand dilut
earn preview select biotech
earn preview select biotech
incorpor septemb common stock senior note offer updat out-year capit rais estim
updat time size expect agili mileston payment base recent management commentari
adjust slightli reflect acceler develop next-gen oral splice modul famili
dysautonomia huntington diseas
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom
earn preview select biotech
estim mm except per share item estimatesconsensu estimatesactualnotesjakafi earn preview select biotech
slightli increas po olumi partner atop dermat decreas out-year penetr
rate base agent profil competit space
decreas out-year olumi penetr ra better reflect progress competit
increas durat treatment jakafi itacitinib acut gvhd base kol feedback
decreas po itacitinib acut gvhd slightli base kol feedback
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand enanta
earn preview select biotech
reconcil model reflect chang near long-term mavyret est base market share rx trend
indic meaning diminish hcv market
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end intercept
earn preview select biotech
updat estim pbc better align rx trend
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc ocaliva licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand celgen celg
earn preview select biotech
capit market estim compani report consensu
increas abraxan pomalyst revenu project base rx pattern
increas po indic follow posit readout aml
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand acadia
outperform pt cover miller
earn preview select biotech
earn preview select biotech
incom statement thousand except pdp revenues- revenu gener oper incom expens incom expens net- net comprehens incom tax net incom per share outstand share outstand dilut appendix
earn preview select biotech
exclud model chang model appear behind tear sheet
earn preview select biotech
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
sarepta inc thousand except per share golodirsen eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens exondi litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
sarepta inc thousand except per share golodirsen eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens exondi litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
incom statement thousand except td- hc- revenu gener oper incom expens incom expens tax provision- comprehens incom net incom per share outstand share outstand dilut
earn preview select biotech
incom statement thousand except revenu gener oper incom expens incom expens tax provision- comprehens incom unreal gain available-for-sal net incom per share outstand share outstand dilut
earn preview select biotech
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom
earn preview select biotech
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc ocaliva licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc ocaliva licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand celg
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand celg
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand
earn preview select biotech
karyopharm thousand except share xpovio sales- xpovio royalties- grant revenu good sold includ royalti hcr gener oper incom pre-tax tax net incom per share outstand share outstand dilut
earn preview select biotech
karyopharm thousand except share xpovio sales- xpovio royalties- grant revenu good sold- gener oper incom pre-tax tax net incom per share outstand share outstand dilut
current incom statement chang
earn preview select biotech
incom statement thousand except grant servic licens total revenu cost sales- research sell gener total oper incom loss interest incom incom expens net pre-tax incom tax provision- net incom earn per share outstand share outstand th-tse
earn preview select biotech
th incom statement usd thousand royalti licens total revenu sale includ research sell gener total oper incom loss interest incom incom expens net- net pre-tax incom tax net incom earn per share outstand share outstand th-tse
earn preview select biotech
th incom statement usd thousand royalti licens total revenu sale includ research sell gener total oper incom loss interest incom incom expens net- net pre-tax incom tax net incom earn per share outstand share outstand glpg
earn preview select biotech
galapago glpg thousand except per share royalties/profit split royalties- revenu sales- oper adjust short-term financi financi net pre-tax result per share outstand share outstand dilut glpg
earn preview select biotech
galapago glpg thousand except per share royalties/profit split royalties- revenu sales- oper adjust short-term financi financi net pre-tax result per share outstand share outstand dilut earn preview select biotech
valuat risk
valuat price target deriv via dcf analysi discount rate
termin growth rate post-taf gener price target support
risk rate price target risk includ gener hiv entrant competit hcv
price pressur commerci scientif complex cellular car-t therapi
efficaci safeti risk pipelin product filgotinib
valuat price target deriv dcf use discount rate
termin growth rate appli follow tecfidera patent expiri valuat
support sector perform rate
risk rate price target risk rate price target includ competit
gener price pressur ms competit sma
valuat price target deriv dcf analysi base busi
discount rate termin growth rate price target support
risk rate price target risk includ lower-than-expect commerci uptak
tez/iva price pressur cf competit emerg safeti issu tripl
valuat price target blend dcf use discount rate termin
growth rate probability-adjust multipl adjust ep discount
analys price target support outperform rate
risk rate price target risk includ slower-than-anticip growth
commerci setback exondi failur gain eu approv exondi failur
success develop gain regulatori approv follow-on exon-skip drug
includ golodirsen casimersen clinic setback gene therapi program
poor perform confirmatori studi lead market remov increas
valuat price target blend dcf use discount rate termin
growth rate sale multipl adjust ep discount analys
multipl discount rate align valuat assumpt biotech
compani similar commerci stage size price target support
risk rate price target risk includ slower-than-expect growth trajectori
ingrezza emerg real-world safeti signal chang physician
prefer ingrezza competitor austedo emerg new
competitor td landscap price pressur driven macro landscap
earn preview select biotech
slower-than-expect orilissa growth inabl garner regulatori approv pipelin
asset due lack efficaci safeti signal concern disrupt
valuat price target blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys price target support outperform rate
risk rate price target risk includ slower-than-expect ex-u launch
translarna dmd slower-than-anticip growth emflaza sale regulatori
pushback gt-aadc neg trial result sma early-stag
valuat price target base dcf discount inci futur cash flow
annual termin growth rate begin jakafi patent expiri
probability-weight potenti favor strateg altern price target
support sector perform rate
risk rate price target downsid risk includ greater-than-expect slow
jakafi use myelofibrosi polycythemia vera inabl obtain regulatori
approv pemigatinib itacitinib topic ruxolitinib failur extend jakafi life
cycl new competit entrant price pressur jakafi olumi emerg
safeti concern market product limit efficaci signal within earlier-
stage pipelin upsid risk includ better expect uptak jakafi olumi
 approv higher-dos olumi develop strategi meaning
life cycl potenti execut transform busi
valuat price target blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys valuat support sector perform rate
risk rate price target risk includ competit hcv nash/pbc
price pressur hcv potenti emerg safeti signal poor efficaci
futur clinic studi high-risk develop path rsv
valuat price target blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys price target support outperform rate
risk rate price target risk includ failur gain approv nash psc
new drug-rel safeti signal emerg unexpect increas frequenc
death liver injuri signal potenti drug-rel toxic challeng control
therapeut window trial real-world set pruritu unmanag cholesterol
increas stagnant growth pbc due label chang conservat among physician
uncertainti epidemiolog restrict reimburs competit
agent
earn preview select biotech
valuat celg pt base announc acquisit price
share cash celg share probability-weight cvr valu
likelihood deal closur valuat justifi sector perform
rate celg base propos acquisit
risk rate price target risk includ failur acquisit close
termin growth rate follow nuplazid patent expiri ep multipl
adjust ep discount analys valuat assumpt
compar commerci biotech compani develop therapeut
neuropsychiatr indic price target support outperform rate
risk rate price target risk includ failur gain approv show meaning
efficaci addit indic drp mdd schizophrenia flatten growth due
lower-than-expect uptak worsen reimburs emerg safeti signal
hamper uptak result remov market lack value-cr
financ greater-than-anticip capit
valuat price target blend dcf use discount rate termin
growth rate probability-adjust price-to-earnings multipl adjust discount
analys valuat support outperform specul risk rate
assign specul risk qualifi given unpredict futur revenu expens
non-revenu gener statu stock price volatil could result substanti
upside/downsid swing anticip valuat
risk rate price target risk includ emerg safeti signal selinexor
failur show consist efficaci signal storm sadal boston selinexor
studi toler issu limit ultim market uptak
valuat price target blend dcf use discount rate termin
growth rate probability-adjust multipl adjust ep discount
analys price target support outperform rate
risk rate price target risk includ slower-than-anticip uptak
heplisav-b competit prevent market penetr uncertainti regard life
cycl ultim longev
valuat price target blend dcf use discount rate
termin growth rate price-to-earnings multipl adjust ep discount
risk rate price target risk includ current futur competit
earn preview select biotech
egrifta manufactur capac lack long-term data safety/efficaci
regulatori uncertainti new formul addit jurisdict
valuat price target blend dcf use discount rate termin
growth rate probability-adjust multipl adjust ep discount
analys valuat support sector perform rate
risk rate price target risk includ emerg safeti issu high regulatori
bar ra drug like filgotinib limit interpret early-stag data
earn preview select biotech
